Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total value of $498,700.00. Following the transaction, the insider now owns 95,648 shares in the company, valued at approximately $4,769,965.76. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Trading Up 2.5 %

NASDAQ AKRO opened at $51.84 on Friday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -13.82 and a beta of -0.11. The business’s fifty day moving average is $37.02 and its 200 day moving average is $31.73.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Canaccord Genuity Group lifted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Morgan Stanley lifted their price target on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Finally, Citigroup lifted their price target on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $75.86.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Akero Therapeutics during the 4th quarter valued at $41,000. Sterling Capital Management LLC lifted its holdings in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after buying an additional 1,582 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares during the period. Quarry LP acquired a new position in Akero Therapeutics during the 4th quarter worth about $83,000. Finally, Eastern Bank acquired a new position in Akero Therapeutics during the 3rd quarter worth about $100,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.